Journal of comparative effectiveness research

Keyphrases

Publications

volume 13, number 8, 2024

Elizabeth A Stewart, Andrea S Lukes, Roberta Venturella, Yulan Li, Elke Hunsche, Rachel B Wagman, Ayman Al-Hendy
Changes in symptom burden and quality of life among women with uterine fibroids receiving relugolix combination therapy: a plain language summary. Journal of comparative effectiveness research 13 (8) (2024)
Alejandra Castanon, Stephen Duffield, Sreeram Ramagopalan, Robert Reynolds
Why is target trial emulation not being used in health technology assessment real-world data submissions? Journal of comparative effectiveness research 13 (8) (2024)
Melvin Skip Olson, Gorana Capkun
The value of evidence and its role in driving product strategy. Journal of comparative effectiveness research 13 (8) (2024)
Alejandra Castanon, Antonia Tsvetanova, Sreeram V Ramagopalan
RWE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 16. Journal of comparative effectiveness research 13 (8) (2024)
Alejandra Castanon, Stephen Duffield, Sreeram Ramagopalan, Robert Reynolds
Why is target trial emulation not being used in health technology assessment real-world data submissions? Journal of comparative effectiveness research 13 (8) (2024)
Elizabeth A Stewart, Andrea S Lukes, Roberta Venturella, Yulan Li, Elke Hunsche, Rachel B Wagman, Ayman Al-Hendy
Changes in symptom burden and quality of life among women with uterine fibroids receiving relugolix combination therapy: a plain language summary. Journal of comparative effectiveness research 13 (8) (2024)
Melvin Skip Olson, Gorana Capkun
The value of evidence and its role in driving product strategy. Journal of comparative effectiveness research 13 (8) (2024)
Victoria Federico Paly, Arvind Dasari, Joleen Hubbard, Tanios Bekaii-Saab, Thihan Padukkavidana, Luis G Hernandez
Adverse event costs of systemic therapies for metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy and biologics in the US. Journal of comparative effectiveness research 13 (8) (2024)
Filip Stanicic, Dimitrije Grbic, Djurdja Vukicevic, Vladimir Zah
Serious treatment-emergent adverse events in chronic low back pain patients treated with buprenorphine or oral opioids: a retrospective commercial claims analysis. Journal of comparative effectiveness research 13 (8) (2024)
Alejandra Castanon, Antonia Tsvetanova, Sreeram V Ramagopalan
RWE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 16. Journal of comparative effectiveness research 13 (8) (2024)
Elke Hunsche, Viatcheslav Rakov, Kayla Scippa, Brooke Witherspoon, Laura McKain
A plain language summary of the perspectives of women who were interviewed about their experiences with uterine fibroids. Journal of comparative effectiveness research 13 (8) (2024)
Victoria Federico Paly, Arvind Dasari, Joleen Hubbard, Tanios Bekaii-Saab, Thihan Padukkavidana, Luis G Hernandez
Adverse event costs of systemic therapies for metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy and biologics in the US. Journal of comparative effectiveness research 13 (8) (2024)
Elke Hunsche, Viatcheslav Rakov, Kayla Scippa, Brooke Witherspoon, Laura McKain
A plain language summary of the perspectives of women who were interviewed about their experiences with uterine fibroids. Journal of comparative effectiveness research 13 (8) (2024)
Alejandra Castanon, Antonia Tsvetanova, Sreeram V Ramagopalan
RWE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 16. Journal of comparative effectiveness research 13 (8) (2024)
Alejandra Castanon, Stephen Duffield, Sreeram Ramagopalan, Robert Reynolds
Why is target trial emulation not being used in health technology assessment real-world data submissions? Journal of comparative effectiveness research 13 (8) (2024)
Melvin Skip Olson, Gorana Capkun
The value of evidence and its role in driving product strategy. Journal of comparative effectiveness research 13 (8) (2024)
Filip Stanicic, Dimitrije Grbic, Djurdja Vukicevic, Vladimir Zah
Serious treatment-emergent adverse events in chronic low back pain patients treated with buprenorphine or oral opioids: a retrospective commercial claims analysis. Journal of comparative effectiveness research 13 (8) (2024)
Victoria Federico Paly, Arvind Dasari, Joleen Hubbard, Tanios Bekaii-Saab, Thihan Padukkavidana, Luis G Hernandez
Adverse event costs of systemic therapies for metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy and biologics in the US. Journal of comparative effectiveness research 13 (8) (2024)
Victoria Federico Paly, Arvind Dasari, Joleen Hubbard, Tanios Bekaii-Saab, Thihan Padukkavidana, Luis G Hernandez
Adverse event costs of systemic therapies for metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy and biologics in the US. Journal of comparative effectiveness research 13 (8) (2024)
Alejandra Castanon, Antonia Tsvetanova, Sreeram V Ramagopalan
RWE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 16. Journal of comparative effectiveness research 13 (8) (2024)
Filip Stanicic, Dimitrije Grbic, Djurdja Vukicevic, Vladimir Zah
Serious treatment-emergent adverse events in chronic low back pain patients treated with buprenorphine or oral opioids: a retrospective commercial claims analysis. Journal of comparative effectiveness research 13 (8) (2024)
Kimberly A Fisher, Mara M Epstein, Ngoc Nguyen, Hassan Fouayzi, Sybil Crawford, Benjamin P Linas, Kathleen M Mazor
COVID-19 clinical trials: who is likely to participate and why? Journal of comparative effectiveness research 13 (8) (2024)
Melvin Skip Olson, Gorana Capkun
The value of evidence and its role in driving product strategy. Journal of comparative effectiveness research 13 (8) (2024)
Elke Hunsche, Viatcheslav Rakov, Kayla Scippa, Brooke Witherspoon, Laura McKain
A plain language summary of the perspectives of women who were interviewed about their experiences with uterine fibroids. Journal of comparative effectiveness research 13 (8) (2024)
Kimberly A Fisher, Mara M Epstein, Ngoc Nguyen, Hassan Fouayzi, Sybil Crawford, Benjamin P Linas, Kathleen M Mazor
COVID-19 clinical trials: who is likely to participate and why? Journal of comparative effectiveness research 13 (8) (2024)

volume 13, number 9, 2024

Winfried H Alsdorf, Joris Diels, Francesca Ghilotti, João Mendes, Teresa Hernando, Patricia Cost, Jordan M Schecter, Nikoletta Lendvai, Nitin Patel, Ana Triguero, Margherita Ursi
Efficacy of CARVYKTI in CARTITUDE-4 versus other conventional treatment regimens for lenalidomide-refractory multiple myeloma using inverse probability of treatment weighting. Journal of comparative effectiveness research 13 (9) (2024)
Sreeram V Ramagopalan, Manuel Gomes, Isabelle Durand-Zaleski, Bill Malcolm, Jose Diaz, Grace Mitchell, Jonathan Pearson-Stuttard, Louis P Garrison
Val (EU) xit: do we need an international ISPOR value flower? Journal of comparative effectiveness research 13 (9) (2024)
Justin W Timbie, Alice Y Kim, Lawrence Baker, Rosemary Li, Thomas W Concannon
Lessons on the use of real-world data in medical device research: findings from the National Evaluation System for Health Technology Test-Cases. Journal of comparative effectiveness research 13 (9) (2024)
Winfried H Alsdorf, Joris Diels, Francesca Ghilotti, João Mendes, Teresa Hernando, Patricia Cost, Jordan M Schecter, Nikoletta Lendvai, Nitin Patel, Ana Triguero, Margherita Ursi
Efficacy of CARVYKTI in CARTITUDE-4 versus other conventional treatment regimens for lenalidomide-refractory multiple myeloma using inverse probability of treatment weighting. Journal of comparative effectiveness research 13 (9) (2024)
Vera Bril, Johannes Lampe, Nichola Cooper, Peter Kiessling, Ann Gardulf
Patient-reported preferences for subcutaneous or intravenous administration of parenteral drug treatments in adults with immune disorders: a systematic review and meta-analysis. Journal of comparative effectiveness research 13 (9) (2024)
Xin Zhang, Natalie Tikhonovsky, Sreeram V Ramagopalan
A review of 25 years of National Institute of Health and Care Excellence decision making. Journal of comparative effectiveness research 13 (9) (2024)
Winfried H Alsdorf, Joris Diels, Francesca Ghilotti, João Mendes, Teresa Hernando, Patricia Cost, Jordan M Schecter, Nikoletta Lendvai, Nitin Patel, Ana Triguero, Margherita Ursi
Efficacy of CARVYKTI in CARTITUDE-4 versus other conventional treatment regimens for lenalidomide-refractory multiple myeloma using inverse probability of treatment weighting. Journal of comparative effectiveness research 13 (9) (2024)
Vera Bril, Johannes Lampe, Nichola Cooper, Peter Kiessling, Ann Gardulf
Patient-reported preferences for subcutaneous or intravenous administration of parenteral drug treatments in adults with immune disorders: a systematic review and meta-analysis. Journal of comparative effectiveness research 13 (9) (2024)
Yves Dauvilliers, Thomas Roth, Richard Bogan, Michael J Thorpy, Anne Marie Morse, Fèri Ascencion, Jennifer Gudeman
Improvements in daytime sleepiness and disrupted nighttime sleep with once-nightly sodium oxybate in people with narcolepsy type 1 and type 2: a plain language summary. Journal of comparative effectiveness research 13 (9) (2024)
Sreeram V Ramagopalan, Manuel Gomes, Isabelle Durand-Zaleski, Bill Malcolm, Jose Diaz, Grace Mitchell, Jonathan Pearson-Stuttard, Louis P Garrison
Val (EU) xit: do we need an international ISPOR value flower? Journal of comparative effectiveness research 13 (9) (2024)
Sreeram V Ramagopalan, Manuel Gomes, Isabelle Durand-Zaleski, Bill Malcolm, Jose Diaz, Grace Mitchell, Jonathan Pearson-Stuttard, Louis P Garrison
Val (EU) xit: do we need an international ISPOR value flower? Journal of comparative effectiveness research 13 (9) (2024)
Vera Bril, Johannes Lampe, Nichola Cooper, Peter Kiessling, Ann Gardulf
Patient-reported preferences for subcutaneous or intravenous administration of parenteral drug treatments in adults with immune disorders: a systematic review and meta-analysis. Journal of comparative effectiveness research 13 (9) (2024)
Winfried H Alsdorf, Joris Diels, Francesca Ghilotti, João Mendes, Teresa Hernando, Patricia Cost, Jordan M Schecter, Nikoletta Lendvai, Nitin Patel, Ana Triguero, Margherita Ursi
Efficacy of CARVYKTI in CARTITUDE-4 versus other conventional treatment regimens for lenalidomide-refractory multiple myeloma using inverse probability of treatment weighting. Journal of comparative effectiveness research 13 (9) (2024)
Sreeram V Ramagopalan, Manuel Gomes, Isabelle Durand-Zaleski, Bill Malcolm, Jose Diaz, Grace Mitchell, Jonathan Pearson-Stuttard, Louis P Garrison
Val (EU) xit: do we need an international ISPOR value flower? Journal of comparative effectiveness research 13 (9) (2024)
Jeff Schein, Martin Cloutier, Marjolaine Gauthier-Loiselle, Maryaline Catillon, Chunyi Xu, Alice Qu, Francesca Lee, Ann Childress
A matching-adjusted indirect comparison of centanafadine versus lisdexamfetamine, methylphenidate and atomoxetine in adults with attention-deficit/hyperactivity disorder: long-term safety and efficacy. Journal of comparative effectiveness research 13 (9) (2024)
Vera Bril, Johannes Lampe, Nichola Cooper, Peter Kiessling, Ann Gardulf
Patient-reported preferences for subcutaneous or intravenous administration of parenteral drug treatments in adults with immune disorders: a systematic review and meta-analysis. Journal of comparative effectiveness research 13 (9) (2024)
Jeff Schein, Martin Cloutier, Marjolaine Gauthier-Loiselle, Maryaline Catillon, Chunyi Xu, Alice Qu, Francesca Lee, Ann Childress
A matching-adjusted indirect comparison of centanafadine versus lisdexamfetamine, methylphenidate and atomoxetine in adults with attention-deficit/hyperactivity disorder: long-term safety and efficacy. Journal of comparative effectiveness research 13 (9) (2024)
Jeff Schein, Martin Cloutier, Marjolaine Gauthier-Loiselle, Maryaline Catillon, Chunyi Xu, Alice Qu, Francesca Lee, Ann Childress
A matching-adjusted indirect comparison of centanafadine versus lisdexamfetamine, methylphenidate and atomoxetine in adults with attention-deficit/hyperactivity disorder: long-term safety and efficacy. Journal of comparative effectiveness research 13 (9) (2024)
Jeff Schein, Martin Cloutier, Marjolaine Gauthier-Loiselle, Maryaline Catillon, Chunyi Xu, Alice Qu, Francesca Lee, Ann Childress
A matching-adjusted indirect comparison of centanafadine versus lisdexamfetamine, methylphenidate and atomoxetine in adults with attention-deficit/hyperactivity disorder: long-term safety and efficacy. Journal of comparative effectiveness research 13 (9) (2024)
Xin Zhang, Natalie Tikhonovsky, Sreeram V Ramagopalan
A review of 25 years of National Institute of Health and Care Excellence decision making. Journal of comparative effectiveness research 13 (9) (2024)
Xin Zhang, Natalie Tikhonovsky, Sreeram V Ramagopalan
A review of 25 years of National Institute of Health and Care Excellence decision making. Journal of comparative effectiveness research 13 (9) (2024)
Justin W Timbie, Alice Y Kim, Lawrence Baker, Rosemary Li, Thomas W Concannon
Lessons on the use of real-world data in medical device research: findings from the National Evaluation System for Health Technology Test-Cases. Journal of comparative effectiveness research 13 (9) (2024)
Grammati Sarri, Luis G Hernandez
The maze of real-world evidence frameworks: from a desert to a jungle! An environmental scan and comparison across regulatory and health technology assessment agencies. Journal of comparative effectiveness research 13 (9) (2024)
Yves Dauvilliers, Thomas Roth, Richard Bogan, Michael J Thorpy, Anne Marie Morse, Fèri Ascencion, Jennifer Gudeman
Improvements in daytime sleepiness and disrupted nighttime sleep with once-nightly sodium oxybate in people with narcolepsy type 1 and type 2: a plain language summary. Journal of comparative effectiveness research 13 (9) (2024)
Grammati Sarri, Luis G Hernandez
The maze of real-world evidence frameworks: from a desert to a jungle! An environmental scan and comparison across regulatory and health technology assessment agencies. Journal of comparative effectiveness research 13 (9) (2024)